Efficacy and safety of granulocyte colony stimulating factor in the treatment of thin endometrium assisted reproductive frozen embryo transfer: a randomized controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049821

Enrollment

Unknown

Registered

2021-08-10

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thin endometrium

Interventions

Experimental group:Granulocyte colony stimulating factor

Control group:Physiological saline

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate, understand and sign the informed consent; 2. Aged 20 to 45 years; 3. Thin endometrium: Endometrial thickness <8mm under ultrasound on the transformation day; 4. Proposed row FET.

Exclusion criteria

Exclusion criteria: 1. Ultrasound and hysteroscopy found abnormal uterine structure such as adenomyosis, submucosal uterine fibroids, intrauterine adhesions, endometritis (positive for CD38 or CD138), endometrial polyps, completely septate uterus, T type uterus, etc.; 2. Other factors affecting embryo implantation such as hydrosalpinx; 3. Patients with severe liver, kidney, heart, and lung dysfunction, potential infection, malignant tumor, and hematological diseases, especially myeloid leukemia patients with no significant reduction in myeloid cells in the bone marrow or those with myeloid cells detected in peripheral blood. myeloid leukemia patients; 4. Combining with neurological and mental disorders and unable to cooperate or unwilling to cooperate; 5. Contraindications of G-CSF (sickle cell anemia, upper respiratory tract infection, pneumonia or chronic neutropenia, autoimmune platelet purpura); 6. Those who have used granulocyte colony-stimulating factor drugs in the past 3 months; 7. The researcher believes that there are any other medical conditions that are not suitable for participating in this trial; 8. Those who do not have 1 high-quality embryo.

Design outcomes

Primary

Measure	Time frame
Endometrial thickness;Clinical pregnancy rate;Implantation rate of embryo transfer;	—

Secondary

Measure	Time frame
Cancel the period rate;Multiple pregnancy rate;Early abortion rate;births;Live-birth rate;Birth weight;Neonatal abnormalities;Neonatal Apgar score;	—

Countries

China

Contacts

Public ContactWang Fang

Lanzhou University Second Hospital

ery_fwang@lzu.edu.cn+86 13919302888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026